A recently published article in Wounds UK concludes that ChloraSolv wound debridement gel shows notably greater antibiofilm activity in vitro, compared to other debridement products and techniques, thus highlighting the promise for ChloraSolv which combines softening of devitalised tissue with antibiofilm activity.
The peer-reviewed article "The in vitro antibiofilm performance of ChloraSolv® Wound Debridement Gel" (authors Dr Daniel Metcalf, Dr Kate Meredith and Susanne Olausson) was recently published in the journal Wounds UK, Vol 19, No 1, 2023. The article is available here (https://www.wounds-uk.com/journals/issue/670/article-details/vitro-antibiofilm-performance-chlorasolv-wound-debridement-gel).
The article concludes that ChloraSolv showed notably greater antibiofilm activity compared to other debridement techniques/products. Although this study only examined the in vitro antibiofilm activity of ChloraSolv, in conjunction with recent clinical studies which focused on easier debridement of devitalised tissue, it highlights the promise for this new wound debridement gel which combines tissue softening and antibiofilm activity.
"We are pleased to see the conclusions from the article, specifically on the superior antibiofilm activity of ChloraSolv compared with other wound debridement techniques/products available to healthcare professionals. The results further strengthens the evidence that ChloraSolv enables convenient, effective and gentle debridement by combining the softening of devitalised tissue with antibiofilm activity", says Björn Larsson, CEO, RLS Global.